# ![@PsychedVantage Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1461655010958315520.png) @PsychedVantage Psychedelic Vantage

Psychedelic Vantage posts on X about $atai, $cmps, $cybn, $ghrs the most. They currently have [-----] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.

### Engagements: [---] [#](/creator/twitter::1461655010958315520/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1461655010958315520/c:line/m:interactions.svg)

- [--] Week [-----] -45%
- [--] Month [------] -80%
- [--] Months [-------] +180%
- [--] Year [-------] +491%

### Mentions: [--] [#](/creator/twitter::1461655010958315520/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1461655010958315520/c:line/m:posts_active.svg)

- [--] Week [--] -44%
- [--] Month [--] -20%
- [--] Months [---] +64%
- [--] Year [---] +213%

### Followers: [-----] [#](/creator/twitter::1461655010958315520/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1461655010958315520/c:line/m:followers.svg)

- [--] Week [-----] +0.34%
- [--] Month [-----] +1.10%
- [--] Months [-----] +27%
- [--] Year [-----] +75%

### CreatorRank: [---------] [#](/creator/twitter::1461655010958315520/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1461655010958315520/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  80.87% [finance](/list/finance)  23.48% [exchanges](/list/exchanges)  4.35% [travel destinations](/list/travel-destinations)  1.74% [currencies](/list/currencies)  0.87% [countries](/list/countries)  0.87% [social networks](/list/social-networks)  0.87% [technology brands](/list/technology-brands)  0.87%

**Social topic influence**
[$atai](/topic/$atai) #3, [$cmps](/topic/$cmps) #7, [$cybn](/topic/$cybn) #2, [$ghrs](/topic/$ghrs) #3, [$mnmd](/topic/$mnmd) #3, [atai life](/topic/atai-life) #4, [in the](/topic/in-the) 9.57%, [$anro](/topic/$anro) 6.96%, [announces](/topic/announces) 6.96%, [investment](/topic/investment) 6.09%

**Top accounts mentioned or mentioned by**
[@c2412345](/creator/undefined) [@4andahalffarm](/creator/undefined) [@atailife](/creator/undefined) [@psychedalpha](/creator/undefined) [@cangermayer](/creator/undefined) [@ataibeckley](/creator/undefined) [@flobrand](/creator/undefined) [@larswilde](/creator/undefined) [@andre_agtc](/creator/undefined) [@behaviorfin](/creator/undefined) [@elmonogran42994](/creator/undefined) [@andreagtc](/creator/undefined) [@compasspathway](/creator/undefined) [@cangermayers](/creator/undefined) [@apeironinvests](/creator/undefined) [@ghresearchplcs](/creator/undefined) [@seckennedy](/creator/undefined) [@matthewherper](/creator/undefined) [@cdcgov](/creator/undefined) [@potus](/creator/undefined)

**Top assets mentioned**
[Atai Life Sciences B.V. (ATAI)](/topic/$atai) [COMPASS Pathways plc (CMPS)](/topic/$cmps) [GH Research PLC (GHRS)](/topic/$ghrs) [Alto Neuroscience, Inc. (ANRO)](/topic/$anro) [AbbVie Inc (ABBV)](/topic/$abbv) [Johnson & Johnson (JNJ)](/topic/$jnj)
### Top Social Posts
Top posts by engagements in the last [--] hours

"Psychedelic company announces a financing Deep Track Capital: Say less $CMPS $MNMD $CYBN $ATAI $GHRS"  
[X Link](https://x.com/PsychedVantage/status/2011061574962667727)  2026-01-13T13:03Z [----] followers, [----] engagements


"A Mebufotenin Melee: Exploring IP and Exclusivity in 5-MeO-DMT Drug Development Across GH Research and Beckley Psytech by @Psyched_Alpha is a good piece to come back to and read. $GHRS $ATAI Link: Since this piece came out there have been many updates such as: Will be interesting to see how this all plays out 🐸 https://www.portasophia.org/newsroom/press-releases/all-pending-claims-rejected-for-gh-research-ireland-ltd-u-s-patent-application-describing-5-meo-dmt-to-treat-depression https://psychedelicalpha.com/news/p%CE%B1-psychedelic-patent-analysis-a-mebufotenin-melee-dec-23-jan-24 GH"  
[X Link](https://x.com/PsychedVantage/status/2007484880087556569)  2026-01-03T16:11Z [----] followers, [----] engagements


"@4andahalfFarm $HELP is later stage than $ATAI. I was specifically criticizing past IR execution and capital allocation toward promotion. In my view that strategy hurt credibility rather than helped it"  
[X Link](https://x.com/PsychedVantage/status/2014396727998951672)  2026-01-22T17:56Z [----] followers, [---] engagements


"Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January [--] [----] 10:00am ET $CMPS https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-to-Host-Webinar-on-Commercial-Preparations-for-Treatment-Resistant-Depression-TRD-and-Clinical-Trial-Plans-for-Post-Traumatic-Stress-Disorder-PTSD-on-January-7-2026-1000am-ET/default.aspx"  
[X Link](https://x.com/PsychedVantage/status/1998362612774699270)  2025-12-09T12:02Z [----] followers, [----] engagements


"With Neuphoria Therapeutics $NEUP and now Vistagen Therapeutics $VTGN reporting unfortunate Phase [--] failures in social anxiety disorder (SAD) a common and often debilitating condition that has become more prevalent since COVID the market remains wide open for a truly effective new treatment. Im hopeful that EMP-01 $ATAI will show promising efficacy data in Q1 measured by change in LSAS total score from baseline to Day [--] with safety and tolerability as the primary endpoint over the same period. Notably there have been no new FDA-approved treatments specifically for SAD in nearly two decades"  
[X Link](https://x.com/PsychedVantage/status/2001292955395518580)  2025-12-17T14:06Z [----] followers, [----] engagements


"Excited to tune into this one There should be a recording in the news/events section of the $CMPS website if you cannot listen in live. Cheers 🍄 January [--] 10:00 am ET Link to webcast: https://t.co/sMO2qd5RfD $CMPS January [--] 10:00 am ET Link to webcast: https://t.co/sMO2qd5RfD $CMPS"  
[X Link](https://x.com/PsychedVantage/status/2008696801415541129)  2026-01-07T00:26Z [----] followers, [---] engagements


"COMPASS Pathways investor presentation January [----] $CMPS https://s204.q4cdn.com/927483861/files/doc_presentation/2026/01/updated/CMPS-investor-presentation_final-for-posting-Jan-7.pdf https://s204.q4cdn.com/927483861/files/doc_presentation/2026/01/updated/CMPS-investor-presentation_final-for-posting-Jan-7.pdf"  
[X Link](https://x.com/PsychedVantage/status/2008916161036005476)  2026-01-07T14:58Z [----] followers, [---] engagements


"$CMPS [--] week high"  
[X Link](https://x.com/PsychedVantage/status/2008977712321581066)  2026-01-07T19:03Z [----] followers, [----] engagements


"@BehaviorFin @ElMonoGran42994 @Andre_AGTC $ATAI does have some more $CMPS shares to dump though. They have been selling around [--] mil each quarter from my memory. I believe they have around [--] million shares left"  
[X Link](https://x.com/PsychedVantage/status/2009285026408501299)  2026-01-08T15:24Z [----] followers, [---] engagements


"$CMPS strategic collaboration partnership I am most interested in currently is with Journey clinical Link: The possibility of people being able to access psilocybin-assisted psychotherapy and potentially with a therapist they already have a relationship with is exciting #CMPS #JourneyClinical https://www.journeyclinical.com https://www.journeyclinical.com Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January [--] [----] 10:00am ET $CMPS https://t.co/JAV6WNHR8M"  
[X Link](https://x.com/PsychedVantage/status/2010003055501025760)  2026-01-10T14:57Z [----] followers, [----] engagements


"Curious if market will appreciate data a bit more when they realize the strength of the IP here (if data is good). Small study but so was Gilgameshs phase 2a with their drug candidate. Unlike Bretisilocin HLP004 is in final IM formulation 😏. Good or good enough $CMPS data will be important for the space but perhaps wont affect $GHRS stock price too much. https://twitter.com/i/web/status/2010749571215880359 https://twitter.com/i/web/status/2010749571215880359"  
[X Link](https://x.com/PsychedVantage/status/2010749571215880359)  2026-01-12T16:23Z [----] followers, [---] engagements


"Ill share what I wrote the other day: I really do like $MNMD right now. If I was more comfortable with a long-term bull thesis for them I would buy in a heartbeat. With $ATAI and $CYBN I like them in the short medium and long term. I truly believe $CYBN can eventually become a buyout target and will probably trim shares along the way if those stocks perform the way I think they will. Once you have a drug that may require more than [--] hours in the clinic I do not know if that can scale. $MNMD is now stating that they expect an 8-hour clinic visit on average though. They have an awesome team and"  
[X Link](https://x.com/PsychedVantage/status/2010813161868345805)  2026-01-12T20:36Z [----] followers, [---] engagements


"AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation $ATAI https://ir.ataibeckley.com/news-releases/news-release-details/ataibeckley-participates-64th-annual-acnp-meeting-two-scientific https://ir.ataibeckley.com/news-releases/news-release-details/ataibeckley-participates-64th-annual-acnp-meeting-two-scientific"  
[X Link](https://x.com/PsychedVantage/status/2012133491438448913)  2026-01-16T12:03Z [----] followers, [---] engagements


"$ATAI Corporate Presentation January [----] https://ir.ataibeckley.com/static-files/93ac20a9-2c59-4ce6-b69d-3add22e34fc3 https://ir.ataibeckley.com/static-files/93ac20a9-2c59-4ce6-b69d-3add22e34fc3"  
[X Link](https://x.com/PsychedVantage/status/2012134621476217162)  2026-01-16T12:07Z [----] followers, [----] engagements


"@4andahalfFarm Yes which doesn't account for any potential future studies with VLS-01 and EMP-01 beyond phase 2"  
[X Link](https://x.com/PsychedVantage/status/2012244603781484681)  2026-01-16T19:24Z [----] followers, [---] engagements


"Psychedelics will also get a dedicated session: a fireside chat with German billionaire investor @C_Angermayer the founder and chair of psychedelics company @ataibeckley. $ATAI https://www.politico.com/news/2025/11/11/jd-vance-rfk-jr-to-attend-maha-summit-00646397 https://www.politico.com/news/2025/11/11/jd-vance-rfk-jr-to-attend-maha-summit-00646397"  
[X Link](https://x.com/PsychedVantage/status/1988338454091231667)  2025-11-11T20:10Z [----] followers, [----] engagements


"$ATAI Corporate Presentation November [----] Updates: EMP-01: Oral R-enantiomer of 34-methylenedioxy-methamphetamine (R-MDMA) for social anxiety disorder (SAD) Completed patient enrollment in the exploratory randomized double-blind placebo-controlled Phase 2a study of EMP-01 to assess the safety tolerability and efficacy in approximately [--] adults with SAD. Anticipate topline results from the exploratory Phase 2a study in the first quarter of [----]. https://ir.ataibeckley.com/static-files/93ac20a9-2c59-4ce6-b69d-3add22e34fc3"  
[X Link](https://x.com/PsychedVantage/status/1988590815556378731)  2025-11-12T12:52Z [----] followers, [----] engagements


"Jake speaks with @flobrand and @LarsWilde Co-Founders of atai Life Sciences (now @ataibeckley) and @COMPASSPathway. In this conversation we discuss their backgrounds what led them into psychedelic drug development and what inspired them to start two of the most influential companies in the space. We cover the major developments of the past year including AbbVies up to $1.2 billion acquisition of Bretisilocin what we know about the compound the type of psychedelic experience it produces and why the deal terms were so significant. Florian and Lars share their views on what this deal means for"  
[X Link](https://x.com/PsychedVantage/status/1998440180181606675)  2025-12-09T17:10Z [----] followers, [----] engagements


"$CYBN $HELP Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq $CYBN https://t.co/nhqzqqkNap Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq $CYBN https://t.co/nhqzqqkNap"  
[X Link](https://x.com/PsychedVantage/status/2001743340837249362)  2025-12-18T19:56Z [----] followers, [----] engagements


"GH Research to Announce IND Status for GH001 $GHRS https://investor.ghres.com/news-releases/news-release-details/gh-research-announce-ind-status-gh001 https://investor.ghres.com/news-releases/news-release-details/gh-research-announce-ind-status-gh001"  
[X Link](https://x.com/PsychedVantage/status/2007195916923789480)  2026-01-02T21:02Z [----] followers, [----] engagements


"In the case you are new to this page here is our interview from [--] months ago with the CEO of GH Research Dr. Villy Valcheva $GHRS Link: https://youtu.be/2L4JGsRx_cYsi=sk5t-P3IAk7GOWAj GH Research to Announce IND Status for GH001 $GHRS https://t.co/7XSR33USjJ https://youtu.be/2L4JGsRx_cYsi=sk5t-P3IAk7GOWAj GH Research to Announce IND Status for GH001 $GHRS https://t.co/7XSR33USjJ"  
[X Link](https://x.com/PsychedVantage/status/2007488900588282068)  2026-01-03T16:27Z [----] followers, [----] engagements


"Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360 $CMPS https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Establishes-Strategic-Collaboration-with-Radial-to-Innovate-Patient-Experience-and-Inform-Potential-Delivery-Model-of-COMP360/default.aspx https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Establishes-Strategic-Collaboration-with-Radial-to-Innovate-Patient-Experience-and-Inform-Potential-Delivery-Model-of-COMP360/default.aspx"  
[X Link](https://x.com/PsychedVantage/status/2008509196497797365)  2026-01-06T12:01Z [----] followers, [---] engagements


"Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD $CMPS https://www.businesswire.com/news/home/20260107267454/en/Compass-Pathways-Announces-FDA-Acceptance-of-IND-Application-for-PTSD-and-Hosts-Webinar-on-PTSD-and-TRDfeedref=JjAwJuNHiystnCoBq_hl-aZB5jvwAGck0gcl1t4KPzrHre1DJVAyGv2KUgXc6KI-rCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3nxKm_sU1fDX96UCOdFPTxd02TcmFSMed6acgQOfyvwRA%3D%3D"  
[X Link](https://x.com/PsychedVantage/status/2008887998730191125)  2026-01-07T13:06Z [----] followers, [---] engagements


"Trimmed around 7% of my $ANRO position in the Roth and bought more $HELP. As always this is not investment advice. Updated neuropsychiatry drug development portfolio allocation (Individual + Roth IRA) Added to $HELP position As always this is not investment advice. I share to stay transparent and spark conversation in the community. -Jake https://t.co/rh56LzDp9S Updated neuropsychiatry drug development portfolio allocation (Individual + Roth IRA) Added to $HELP position As always this is not investment advice. I share to stay transparent and spark conversation in the community. -Jake"  
[X Link](https://x.com/PsychedVantage/status/2010747666230034504)  2026-01-12T16:16Z [----] followers, [----] engagements


"Long post 🚨 $CMPS $MNMD $CYBN $ATAI $GHRS Yes this is a small dataset but we are consistently seeing better outcomes across studies evaluating psychedelics as adjunctive treatments. Whether this reflects a true synergistic effect or simply that patients are in a better psychological or physiological state when they are not required to withdraw from background medications they have been taking for years is not clear yet. It could be both. Janssen originally evaluated Spravato as an adjunctive therapy in patients who were starting a new oral antidepressant. In a monotherapy study they"  
[X Link](https://x.com/PsychedVantage/status/1997166696142934049)  2025-12-06T04:50Z [----] followers, [----] engagements


"Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq $CYBN https://ir.cybin.com/investors/news/news-details/2025/Cybin-to-Transfer-U-S--Stock-Exchange-Listing-to-Nasdaq/default.aspx https://ir.cybin.com/investors/news/news-details/2025/Cybin-to-Transfer-U-S--Stock-Exchange-Listing-to-Nasdaq/default.aspx"  
[X Link](https://x.com/PsychedVantage/status/2001651519452762148)  2025-12-18T13:51Z [----] followers, [----] engagements


"Nice day for $CYBN on strong volume approaching key warrant strike levels. Looking forward to Q1 data in GAD (with patients on background medication and co-morbid depression allowed in study) with CYB004 (deuterated NN-DMT delivered via intramuscular injection). CYB004 is protected by a U.S. composition of matter patent expected to provide coverage until at least [----]. https://twitter.com/i/web/status/2003566857480016165 https://twitter.com/i/web/status/2003566857480016165"  
[X Link](https://x.com/PsychedVantage/status/2003566857480016165)  2025-12-23T20:42Z [----] followers, [----] engagements


"I like $CMPS a lot but do not currently hold the stock. I personally like to make concentrated bets in the space and I also try not to get married to a stock. I think you can make a great bull thesis for all big five publicly traded companies right now. $CMPS has an exceptional team and I am confident they will build a successful company. I happen to be more optimistic about the compounds $ATAI and $CYBN are working with (and no not just because BPL-003 VLS-01 and CYB004 are shorter acting though this is a bonus) and with $CYBN especially I view the stock as being incredibly undervalued as of"  
[X Link](https://x.com/PsychedVantage/status/2007927926344589371)  2026-01-04T21:31Z [----] followers, [---] engagements


"One lesson Ive learned as a retail investor in the neuropsych space: I shouldnt assume the market or competition is always aware of all publicly available information. $ANRO looked too good to be true when it was an $80M market cap company so I sized it small. That position is now much larger. Plenty of risk remains but Im holding. Another name I think is currently being overlooked is $CYBN. CYB004 (short-duration psychedelic) has composition-of-matter IP and data expected in Q1 [----] 🤞 This is not investment advice and reflects my personal opinion."  
[X Link](https://x.com/PsychedVantage/status/2000615445603209271)  2025-12-15T17:14Z [----] followers, [----] engagements


"Meeting the Promise of Psychedelics Panel: Expected Trends for [----] @ Sachs_NIF $CMPS $DFTX $HELP $ATAI $GHRS https://youtu.be/hGhSBPlzHLYsi=WD_AmS-FMT0P0GRc https://youtu.be/hGhSBPlzHLYsi=WD_AmS-FMT0P0GRc"  
[X Link](https://x.com/PsychedVantage/status/2022061749714006331)  2026-02-12T21:34Z [----] followers, [----] engagements


".@C_Angermayers @ApeironInvests increases its stake in $ATAI https://ir.atai.life/node/8796/html https://ir.atai.life/node/8796/html"  
[X Link](https://x.com/anyuser/status/1892350493994758513)  2025-02-19T23:08Z [----] followers, [----] engagements


"atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares $ATAI https://ir.atai.life/news-releases/news-release-details/atai-life-sciences-announces-closing-public-offering-and-full https://ir.atai.life/news-releases/news-release-details/atai-life-sciences-announces-closing-public-offering-and-full"  
[X Link](https://x.com/anyuser/status/1892545583627243544)  2025-02-20T12:03Z [----] followers, [----] engagements


"I agree with this bull thesis. But what excites me even more is not just the potential for better scalability I genuinely believe NN-DMT and 5-MeO-DMT have a strong chance of demonstrating superior efficacy over psilocybin for the treatment of depression. Of course different psychedelics will work better for different people. But overall I see greater therapeutic upside in 5-MeO-DMT and NN-DMT not just in terms of scalability but also in terms of clinical impact. More data is needed. These are exciting times -Jake Why I love $ATAI & just invested USD 22.75m more to increase my stake from"  
[X Link](https://x.com/anyuser/status/1894083020753109281)  2025-02-24T17:52Z [----] followers, [----] engagements


"atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression $ATAI https://ir.atai.life/news-releases/news-release-details/atai-life-sciences-announces-completion-enrollment-phase-2b https://ir.atai.life/news-releases/news-release-details/atai-life-sciences-announces-completion-enrollment-phase-2b"  
[X Link](https://x.com/anyuser/status/1897256314092630155)  2025-03-05T12:02Z [----] followers, [---] engagements


"In case you missed it here is our most recent interview with Dr. Villy Valcheva CEO of GH Research: Topics of this interview include: Dr. Valcheva's background as a physician and experience working in pharma/biotech. The company's thought process behind choosing mebufotenin an inhalation route of administration and an individualized dosing regimen. GH001 demonstrating consistent antidepressant efficacy with re-treatment in the company's phase 2b trial in TRD. GH Research taking a unique approach with its Phase 2b trial design compared to other psychedelic drug developers. With the recent"  
[X Link](https://x.com/PsychedVantage/status/1899177949166784648)  2025-03-10T19:18Z [----] followers, [---] engagements


"FDA commissioner says research on psychedelic treatment top priority' On Balance $GHRS $MNMD $CMPS $ATAI $CYBN https://www.youtube.com/watchv=KEQFKBME668&t=32s https://www.youtube.com/watchv=KEQFKBME668&t=32s"  
[X Link](https://x.com/PsychedVantage/status/1923742128770826395)  2025-05-17T14:07Z [----] followers, 17.5K engagements


"There are ongoing clinical trials that are going to read out sometime soon and we have to take an expeditious and rapid review of that data - FDA commissioner Dr. Marty Makary $GHRS $MNMD $CMPS $ATAI $CYBN FDA commissioner says research on psychedelic treatment top priority' On Balance https://t.co/TsiU0b9SJk $GHRS $MNMD $CMPS $ATAI $CYBN FDA commissioner says research on psychedelic treatment top priority' On Balance https://t.co/TsiU0b9SJk $GHRS $MNMD $CMPS $ATAI $CYBN"  
[X Link](https://x.com/PsychedVantage/status/1923752228445106268)  2025-05-17T14:47Z [----] followers, [----] engagements


"atai Life Sciences Announces Positive Topline Data from Part [--] of Beckley Psytechs Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression $ATAI https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-announces-positive-topline-data-part-2 https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-announces-positive-topline-data-part-2"  
[X Link](https://x.com/anyuser/status/1924782992666349996)  2025-05-20T11:03Z [----] followers, [----] engagements


"GH Research poster presentations: $GHRS https://investor.ghres.com/node/7926/html GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology [----] Annual Meeting $GHRS https://t.co/vCLzFWArIs https://investor.ghres.com/node/7926/html GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology [----] Annual Meeting $GHRS https://t.co/vCLzFWArIs"  
[X Link](https://x.com/PsychedVantage/status/1925182266918965291)  2025-05-21T13:29Z [----] followers, [----] engagements


"@SecKennedy @matthewherper @CDCgov @POTUS @NIHDirector_Jay @DrMakaryFDA Long covid has entered the chat"  
[X Link](https://x.com/anyuser/status/1927382757472178580)  2025-05-27T15:13Z [----] followers, 24.4K engagements


"Hello everyone Jake here: I will be outside of the country for most of June so this page might be a bit quiet for a couple of weeks. A recap/some updates: $CMPS COMP005 top-line [--] week data is currently on track to read out in late June. $ATAI BPL-003 in TRD and RL-007 in CIAS (cognitive impairment associated with schizophrenia) are expected to read out mid-year. Recent interview with CEO Dr. Srinivas Rao on Proactive Investors YouTube channel commenting on timing: Well see which one is first $CYBN CYB004 in GAD. Recent interview with Water Tower Research and CEO Doug Drysdale commenting the"  
[X Link](https://x.com/anyuser/status/1929178772936507453)  2025-06-01T14:10Z [----] followers, [----] engagements


"Portfolio Update: As always this is not financial advice. I share updates on my psychedelic drug development portfolio to stay transparent and spark conversation in the community. Today Ive added $CMPS to my portfolio. I now hold $ATAI $GHRS and $CMPS. 🍄🐸 -Jake"  
[X Link](https://x.com/PsychedVantage/status/1937509025811173855)  2025-06-24T13:52Z [----] followers, [----] engagements


"$CMPS $MNMD $CYBN $GHRS $ATAI $JNJ"  
[X Link](https://x.com/anyuser/status/1938342583677096271)  2025-06-26T21:04Z [----] followers, [----] engagements


"atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression $ATAI https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-and-beckley-psytech-announce-positive-topline https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-and-beckley-psytech-announce-positive-topline"  
[X Link](https://x.com/anyuser/status/1939989700854292712)  2025-07-01T10:09Z [----] followers, [----] engagements


"BPL-003 Phase 2b Data Presentation $ATAI https://ir.atai.com/static-files/daa99855-29e4-492f-9c84-1ae4cc039284 https://ir.atai.com/static-files/daa99855-29e4-492f-9c84-1ae4cc039284"  
[X Link](https://x.com/anyuser/status/1940108928756367522)  2025-07-01T18:03Z [----] followers, [---] engagements


"Current psychedelic drug development portfolio allocation (Individual + Roth IRA) If youve followed this account for a while you know these holdings have changed quite a bit over time. What does your breakdown look like Jake $CMPS $MNMD $CYBN $ATAI $GHRS"  
[X Link](https://x.com/PsychedVantage/status/1940154348606042329)  2025-07-01T21:03Z [----] followers, [----] engagements


"Welcome back Cathie. $ATAI $ARKG https://www.investing.com/news/company-news/cathie-woods-ark-etf-adjusts-portfolio-buys-tesla-and-atai-stock-93CH-4120225 https://www.investing.com/news/company-news/cathie-woods-ark-etf-adjusts-portfolio-buys-tesla-and-atai-stock-93CH-4120225"  
[X Link](https://x.com/anyuser/status/1940230458853503038)  2025-07-02T02:06Z [----] followers, [----] engagements


"Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study https://www.sciencedirect.com/science/article/pii/S0010440X25000471 https://www.sciencedirect.com/science/article/pii/S0010440X25000471"  
[X Link](https://x.com/PsychedVantage/status/1940778251397615842)  2025-07-03T14:22Z [----] followers, [---] engagements


"GH Research stock awaits FDA response on clinical hold says Canaccord $GHRS https://www.investing.com/news/analyst-ratings/gh-research-stock-awaits-fda-response-on-clinical-hold-says-canaccord-93CH-4129814 https://www.investing.com/news/analyst-ratings/gh-research-stock-awaits-fda-response-on-clinical-hold-says-canaccord-93CH-4129814"  
[X Link](https://x.com/PsychedVantage/status/1943733361270272255)  2025-07-11T18:05Z [----] followers, [---] engagements


"@DrNeilStone This is not an opinion its a fact"  
[X Link](https://x.com/anyuser/status/1944437777824628837)  2025-07-13T16:44Z [----] followers, [----] engagements


"Current members of the Association for Prescription Psychedelics (@PsychedelicsRX) Mission statement: To educate and advocate for the development and accessibility of safe and effective prescription psychedelic medicines for patients. https://www.psychedelicsrx.org https://www.psychedelicsrx.org"  
[X Link](https://x.com/anyuser/status/1945626636914704577)  2025-07-16T23:28Z [----] followers, [----] engagements


"Very informative episode A big thank you to @AdvisorShares and @ElemerPiros #AlphaNooner Deep Dive into Psychedelic Biotech with Elemer Piros PhD https://t.co/Ck4JBeVMuW #AlphaNooner Deep Dive into Psychedelic Biotech with Elemer Piros PhD https://t.co/Ck4JBeVMuW"  
[X Link](https://x.com/anyuser/status/1947769079475159485)  2025-07-22T21:21Z [----] followers, [---] engagements


"Updates: Sold out of $GHRS position today Current neuropsychiatry drug development portfolio allocation (Individual + Roth IRA) $ATAI $CMPS $ANRO $VTGN As always this is not investment advice. -Jake Current psychedelic drug development portfolio allocation (Individual + Roth IRA) If youve followed this account for a while you know these holdings have changed quite a bit over time. What does your breakdown look like Jake $CMPS $MNMD $CYBN $ATAI $GHRS https://t.co/fGl81TZhVm Current psychedelic drug development portfolio allocation (Individual + Roth IRA) If youve followed this account for a"  
[X Link](https://x.com/anyuser/status/1948024323500867961)  2025-07-23T14:16Z [----] followers, [----] engagements


"GH Research R&D Update July [----] $GHRS Presentation: https://investor.ghres.com/static-files/68e55af4-a7da-499c-aa99-2e0656b6ab89 https://investor.ghres.com/static-files/68e55af4-a7da-499c-aa99-2e0656b6ab89"  
[X Link](https://x.com/PsychedVantage/status/1948125201058738371)  2025-07-23T20:56Z [----] followers, [---] engagements


"I have cash sitting on the sidelines to buy names I view as being undervalued in the neuropsychiatry space. Tickers I am looking at include $ATAI $CYBN $VTGN $ANRO $DRUG $NEUP. I am already overweight $ATAI but the news-flow I am anticipating in the coming months makes me inclined to buy more if the market continues to overreact to RL-007 miss (a drug I and many others were not expecting to meet its primary endpoint in CIAS). Along with several clinical trial readouts with de-risked psychedelic assets anticipated in the coming months for $ATAI an announcement of breakthrough therapy"  
[X Link](https://x.com/anyuser/status/1948870767963214088)  2025-07-25T22:19Z [----] followers, [----] engagements


"On the buying side ARK also picked up [------] shares of ATAI LIFE SCIENCES NV (NASDAQ: $ATAI) through its $ARKG ETF valued at $1748411 https://www.investing.com/news/company-news/cathie-woods-ark-buys-amd-and-alphabet-stock-sells-coinbase-and-robinhood-93CH-4156293 https://www.investing.com/news/company-news/cathie-woods-ark-buys-amd-and-alphabet-stock-sells-coinbase-and-robinhood-93CH-4156293"  
[X Link](https://x.com/PsychedVantage/status/1949989195004465283)  2025-07-29T00:23Z [----] followers, [----] engagements


"AbbVie in Talks to Acquire Gilgamesh in $1 Billion Deal https://www.bloomberg.com/news/articles/2025-07-30/abbvie-is-said-in-talks-to-acquire-gilgamesh-in-1-billion-dealsrnd=prognosis&embedded-checkout=true https://www.bloomberg.com/news/articles/2025-07-30/abbvie-is-said-in-talks-to-acquire-gilgamesh-in-1-billion-dealsrnd=prognosis&embedded-checkout=true"  
[X Link](https://x.com/PsychedVantage/status/1950686113448010239)  2025-07-30T22:33Z [----] followers, [----] engagements


"Some thoughts on challenging psychedelic experiences reported with 5-MeO-DMT. I would love to hear others thoughts as well. $CMPS $MNMD $CYBN $ATAI $GHRS I can definitely understand the hesitation around 5-MeO-DMT. To put things into perspective people can also have extremely challenging experiences with psilocybin and LSD even in a clinical setting. As many of you know many (though not all) people end up reporting benefits from these challenging experiences. Research from @JulesEvans11 in the sample from The Challenging Psychedelic Experiences Project found that the majority stated they"  
[X Link](https://x.com/anyuser/status/1954187832018244070)  2025-08-09T14:27Z [----] followers, [----] engagements


"Updated catalyst table for $ATAI - This table doesnt include FDA Breakthrough Therapy Designation for BPL-003 (which I think is likely though not guaranteed). - Something important to note: Fully funded through multiple near-term milestones does not include initiating the Phase [--] trial for BPL-003 in TRD. I mention this now because people often get confused when a company raises capital despite showing runway into [----]. Companies rarely wait until the last minute to raise. Does $ATAI form a partnership in the near to medium term 🤔"  
[X Link](https://x.com/anyuser/status/1958557176097571125)  2025-08-21T15:49Z [----] followers, [----] engagements


"AbbVie to buy Gilgamesh Pharma's depression drug for up to $1.2 billion https://www.reuters.com/legal/transactional/abbvie-buy-gilgamesh-pharmas-depression-drug-up-12-billion-2025-08-25/ https://www.reuters.com/legal/transactional/abbvie-buy-gilgamesh-pharmas-depression-drug-up-12-billion-2025-08-25/"  
[X Link](https://x.com/PsychedVantage/status/1959968656995094845)  2025-08-25T13:18Z [----] followers, 17.6K engagements


"Huge validation and yes for programs that DONT skip the trip 😉 $CMPS $MNMD $CYBN $ATAI $GHRS AbbVie to buy Gilgamesh Pharma's depression drug for up to $1.2 billion https://t.co/tzj7RPxLH7 AbbVie to buy Gilgamesh Pharma's depression drug for up to $1.2 billion https://t.co/tzj7RPxLH7"  
[X Link](https://x.com/anyuser/status/1959976689326256335)  2025-08-25T13:50Z [----] followers, [----] engagements


"Updated neuropsychiatry drug development portfolio allocation (Individual + Roth IRA) I welcome back an old friend into the portfolio: $CYBN As always this is not investment advice. I share to stay transparent and spark conversation in the community. -Jake"  
[X Link](https://x.com/anyuser/status/1960008246296789363)  2025-08-25T15:55Z [----] followers, [----] engagements


"From: American College of Neuropsychopharmacology Annual Meeting December 8-11 [----] Poster #M59: SPL026 (DMT fumarate) in combination with Selective Serotonin Reuptake Inhibitors (SSRIs) for patients with Major Depressive Disorder (MDD) Absolutely fascinating data here (yes small sample size). This was looking at IV NN-DMT. $CYBN CYB004 (Deuterated NN-DMT IM formulation) is expected to elicit a [--] minute experience. Peak effects in 3-5 min (Seems ideal for GAD patients not much time to sit around waiting). Compared to IV NN-DMT patients will have more time in the CYB004 experience. Most"  
[X Link](https://x.com/PsychedVantage/status/1961554512197693948)  2025-08-29T22:20Z [----] followers, [----] engagements


"Compass Pathways Announces Publication of Results from Phase [--] Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder $CMPS https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Announces-Publication-of-Results-from-Phase-2-Study-of-COMP360-Psilocybin-for-Post-Traumatic-Stress-Disorder/default.aspx https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Announces-Publication-of-Results-from-Phase-2-Study-of-COMP360-Psilocybin-for-Post-Traumatic-Stress-Disorder/default.aspx"  
[X Link](https://x.com/PsychedVantage/status/1962825819702640714)  2025-09-02T10:31Z [----] followers, [----] engagements


"Will BPL-003 be the first short-duration psychedelic to be granted FDA Breakthrough Therapy Designation 🤔 🐸 $ATAI Only [--] more trading days left in September and $ATAI is expected to release Open Label Extension (OLE) data for BPL-003 (5-MeO-DMT) by the end of the month. I hope youre as excited as I am 🐸🚀 Only [--] more trading days left in September and $ATAI is expected to release Open Label Extension (OLE) data for BPL-003 (5-MeO-DMT) by the end of the month. I hope youre as excited as I am 🐸🚀"  
[X Link](https://x.com/anyuser/status/1966539367901544905)  2025-09-12T16:28Z [----] followers, [----] engagements


"$ATAI $ARKG Here's every move Cathie Wood and Ark Invest made in the stock market today 9/17 https://t.co/VicfItGdVl Here's every move Cathie Wood and Ark Invest made in the stock market today 9/17 https://t.co/VicfItGdVl"  
[X Link](https://x.com/PsychedVantage/status/1968469557057593617)  2025-09-18T00:18Z [----] followers, [----] engagements


"atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression $ATAI https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-and-beckley-psytech-report-positive-phase-2a https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-and-beckley-psytech-report-positive-phase-2a"  
[X Link](https://x.com/anyuser/status/1970443777543487947)  2025-09-23T11:03Z [----] followers, [----] engagements


"Updated neuropsychiatry drug development portfolio allocation (Individual + Roth IRA) Today I sold around 14% of my $ATAI position and for a simple reason: Not only was $ATAI very overweight in my neuropsychiatry drug development portfolio it was starting to make up an uncomfortably large share of my overall net worth. (I still think this stock has a lot of upside potential in the short medium and longterm/not financial or investment advice). As always this is not investment advice. I share to stay transparent and spark conversation in the community. -Jake"  
[X Link](https://x.com/anyuser/status/1970591031256052027)  2025-09-23T20:48Z [----] followers, [----] engagements


"Updated neuropsychiatry drug development portfolio allocation (Individual + Roth IRA) I cut losses with $CYBN and spread money around to $ATAI $CMPS $VTGN $NEUP (new position) $VOO and $VTI As always this is not investment advice. I share to stay transparent and spark conversation in the community. -Jake"  
[X Link](https://x.com/anyuser/status/1973055674968908280)  2025-09-30T16:01Z [----] followers, [----] engagements


"Updated neuropsychiatry drug development portfolio allocation (Individual + Roth IRA) Trimmed 8% of my $ANRO position after the big move today. Looking forward to $NEUP phase [--] data with BNC-210 in SAD expected this month (partial exit plan already in place). I will likely continue trimming small amounts of $ATAI if we get another leg up from here. Profits are being redeployed into a mix of $VOO $VTI and a reserve of cash sitting on the sidelines. As always this is not investment advice. I share to stay transparent and spark conversation in the community. -Jake"  
[X Link](https://x.com/PsychedVantage/status/1974220848455200778)  2025-10-03T21:11Z [----] followers, [----] engagements


"$ATAI $ARKG Here's every move Cathie Wood and Ark Invest made in the stock market today 10/6 https://t.co/0kUSsD0BBu Here's every move Cathie Wood and Ark Invest made in the stock market today 10/6 https://t.co/0kUSsD0BBu"  
[X Link](https://x.com/anyuser/status/1975370518707716236)  2025-10-07T01:20Z [----] followers, [----] engagements


"$ATAI October [----] Corporate Presentation https://ir.atai.com/static-files/93ac20a9-2c59-4ce6-b69d-3add22e34fc3 https://ir.atai.com/static-files/93ac20a9-2c59-4ce6-b69d-3add22e34fc3"  
[X Link](https://x.com/PsychedVantage/status/1975579808848339176)  2025-10-07T15:11Z [----] followers, [----] engagements


"atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003 Underscoring its Potential in Treatment-Resistant Depression $ATAI https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-and-beckley-psytech-announce-us-fda https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-and-beckley-psytech-announce-us-fda"  
[X Link](https://x.com/PsychedVantage/status/1978917049125736951)  2025-10-16T20:12Z [----] followers, [----] engagements


"atai Life Sciences Announces Proposed Public Offering of Common Shares $ATAI https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-announces-proposed-public-offering-common-0 https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-announces-proposed-public-offering-common-0"  
[X Link](https://x.com/anyuser/status/1978917961189490898)  2025-10-16T20:16Z [----] followers, [----] engagements


"Indeed. Very exciting news. 🐸 Interested to see the pricing of the proposed public offering. $ATAI Will BPL-003 be the first short-duration psychedelic to be granted FDA Breakthrough Therapy Designation 🤔 🐸 $ATAI Will BPL-003 be the first short-duration psychedelic to be granted FDA Breakthrough Therapy Designation 🤔 🐸 $ATAI"  
[X Link](https://x.com/anyuser/status/1978931365769892063)  2025-10-16T21:09Z [----] followers, [----] engagements


"atai Life Sciences Announces Pricing of Public Offering of Common Shares $ATAI https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-announces-pricing-public-offering-common-0 https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-announces-pricing-public-offering-common-0"  
[X Link](https://x.com/anyuser/status/1979012977836601377)  2025-10-17T02:33Z [----] followers, [----] engagements


"Close Priced at $5.48. Great to see $ATAI raising at this valuation curious to see which investors participated when that list comes out. atai Life Sciences Announces Pricing of Public Offering of Common Shares $ATAI https://t.co/HlKMgbNHe3 atai Life Sciences Announces Pricing of Public Offering of Common Shares $ATAI https://t.co/HlKMgbNHe3"  
[X Link](https://x.com/anyuser/status/1979014988116181188)  2025-10-17T02:41Z [----] followers, [----] engagements


"@C_Angermayer @atai_life Congratulations @C_Angermayer and to the entire team at @atai_life and @BeckleyPsytech"  
[X Link](https://x.com/PsychedVantage/status/1979166155957772600)  2025-10-17T12:42Z [----] followers, [---] engagements


"Hi hey you yeah you the people who always comment after a company raises more cash to fund the development of their product candidates. Not all dilution is created equally. $ATAI"  
[X Link](https://x.com/anyuser/status/1979253708123762877)  2025-10-17T18:30Z [----] followers, [----] engagements


"$MNMD surpasses $1 billion dollar market cap"  
[X Link](https://x.com/PsychedVantage/status/1979271935524556879)  2025-10-17T19:42Z [----] followers, [----] engagements


"$CMPS $MNMD $CYBN $ATAI $GHRS What I love most about making investment decisions in the psychedelic drug development space: Evaluating programs not necessarily based on the drugs mechanism of action or receptor binding profile but on the subjective experience the drug produces among many other factors. However these elements are of course deeply connected. I believe non-hallucinogenic neuroplastogens will be effective in mood and anxiety disorders but I am most excited about their potential in neurological disorders. If these compounds prove effective for mood and anxiety disorders I expect"  
[X Link](https://x.com/PsychedVantage/status/1979364985102045671)  2025-10-18T01:52Z [----] followers, [----] engagements


"Updated neuropsychiatry drug development portfolio allocation (Individual + Roth IRA) Have been trimming small amounts of $CMPS and $ATAI this past week (essentially forcing myself to sell small amounts of $ATAI with each new high). As I have previously shared this is due to $ATAI starting to make up an uncomfortable portion of my overall net worth. I have a core position I plan on holding for longterm but plans can always change if I feel the stock starts to become overvalued (I dont think it is right now/not financial advice). Took quick *70+% gains on $NEUP in the roth. We shall see if I"  
[X Link](https://x.com/anyuser/status/1979599242562838905)  2025-10-18T17:23Z [----] followers, [----] engagements


"What a day what a year. Neuropsych portfolio up over 350% YTD. Euphoria kicked in today when I saw the value of the portfolio. This was sign to me that I needed to take more money off the table. I have trimmed around 20% of the portfolio this year. Holding onto $ANRO for dear life though. Trimmed tiny amounts of $ATAI today (75% of reason it takes up such a large chunk of the neuropsych portfolio is because I would still buy at todays prices and 25% is emotional attachment which is something I really need to address). Also sold a bit more $CMPS today. I think $ATAI $CMPS $ANRO and $VTGN (more"  
[X Link](https://x.com/anyuser/status/1980313300014346306)  2025-10-20T16:40Z [----] followers, [----] engagements


"atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares $ATAI https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-announces-closing-public-offering-and-full-0 https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-announces-closing-public-offering-and-full-0"  
[X Link](https://x.com/anyuser/status/1980386736661491972)  2025-10-20T21:32Z [----] followers, [----] engagements


"Jake here: Like Christian I am also biased towards $ATAI. I too wonder what BPL-003 alone should be valued. Later stage than Gilgamesh program larger dataset in harder to treat depression and superior drug delivery technology (IMO). Awesome overview of @atai_life 👇 https://t.co/7dpEVbrzRI https://t.co/7dpEVbrzRI"  
[X Link](https://x.com/anyuser/status/1980679702647107673)  2025-10-21T16:56Z [----] followers, [----] engagements


"Tbh not sure what to make of it. I personally (again personally) wrote off that program 1-2 years ago. Agreed cardiac issues make it very difficult to develop this psychedelic. It isnt mentioned anywhere in atai investor presentation or website. More than happy with BPL-003 VLS-01 EMP-01 and discovery program moving forward. -Jake https://twitter.com/i/web/status/1980885107863908808 https://twitter.com/i/web/status/1980885107863908808"  
[X Link](https://x.com/PsychedVantage/status/1980885107863908808)  2025-10-22T06:33Z [----] followers, [--] engagements


"@ikkjrpp @atai_life I certainly think that in a medical setting with trained mental health professionals involved psychedelics have a lot of potential (key word here) to safely and effectively treat anxiety disorders. -Jake"  
[X Link](https://x.com/PsychedVantage/status/1980886233246233086)  2025-10-22T06:37Z [----] followers, [--] engagements


"It is simpler in Canada to access medical assistance in dying today than to access MDMA or psilocybin treatments. -@Nickkadysh CEO of @PharmAlaBiotech Yesterday PharmAla CEO Nick Kadysh joined PsyCan alongside military veterans in Ottawa to urge the Canadian government to remove barriers and make life saving therapies more accessible. Urgent change is needed as the number of Canadians suffering from mental health disorders https://t.co/AaKMiC7rol Yesterday PharmAla CEO Nick Kadysh joined PsyCan alongside military veterans in Ottawa to urge the Canadian government to remove barriers and make"  
[X Link](https://x.com/PsychedVantage/status/1980988496161698138)  2025-10-22T13:23Z [----] followers, [----] engagements


"Okay $ATAI. I see you trying to shorten the duration of EMP-01 👀 Looking forward to seeing data with EMP-01 in Q1 [----] https://www.nualtis.com/products-and-pipeline/overview https://www.nualtis.com/products-and-pipeline/overview"  
[X Link](https://x.com/PsychedVantage/status/1981148382765949097)  2025-10-22T23:59Z [----] followers, [----] engagements


"@4andahalfFarm @atai_life $CMPS invested 500k in seed round/8% stake. With further financing rounds the impact of $CMPS delix investment for $ATAI is most likely insignificant. $ATAI is also continuously selling off stake in $CMPS to fund their own programs. -Jake"  
[X Link](https://x.com/PsychedVantage/status/1984058377295818988)  2025-10-31T00:42Z [----] followers, [--] engagements


"Hello everyone I deleted a post today sharing thoughts on adverse-event reporting in clinical trials involving 5-MeO-DMT. After looking into it further I realized I was forming a strong opinion based on incomplete information. Im deeply interested in the nuances of psychedelic drug development and I always aim to share accurate well-supported information. Sometimes I miss the mark and when I do Id rather correct course than let something misleading circulate. Thanks to everyone who engages thoughtfully with this space. Were all continuing to learn. -Jake"  
[X Link](https://x.com/PsychedVantage/status/1985491172840915083)  2025-11-03T23:35Z [----] followers, [----] engagements


"Compass Pathways Announces Third Quarter [----] Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months $CMPS https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Announces-Third-Quarter-2025-Financial-Results-and-Business-Highlights-Including-Acceleration-of-Commercial-Launch-Plans-by-9-12-Months/default.aspx"  
[X Link](https://x.com/anyuser/status/1985673050520494180)  2025-11-04T11:38Z [----] followers, [----] engagements


"COMPASS Pathways investor presentation November [----] $CMPS https://s204.q4cdn.com/927483861/files/doc_presentation/2025/11/Compass-Pathways-deck_new-template_11-3-2025_v2-1.pdf https://s204.q4cdn.com/927483861/files/doc_presentation/2025/11/Compass-Pathways-deck_new-template_11-3-2025_v2-1.pdf"  
[X Link](https://x.com/PsychedVantage/status/1985734159621333239)  2025-11-04T15:41Z [----] followers, [----] engagements


"atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley a Global Leader in Transformative Mental Health Therapies $ATAI https://ir.ataibeckley.com/news-releases/news-release-details/atai-life-sciences-and-beckley-psytech-announce-successful https://ir.ataibeckley.com/news-releases/news-release-details/atai-life-sciences-and-beckley-psytech-announce-successful"  
[X Link](https://x.com/anyuser/status/1986041581451784662)  2025-11-05T12:03Z [----] followers, [----] engagements


"Corporate Presentation GH Research PLC (NASDAQ: $GHRS) November [----] https://investor.ghres.com/static-files/b2dd9ece-7c4f-4f54-ba96-71ed0a772ee1 https://investor.ghres.com/static-files/b2dd9ece-7c4f-4f54-ba96-71ed0a772ee1"  
[X Link](https://x.com/PsychedVantage/status/1986425386494771599)  2025-11-06T13:28Z [----] followers, [---] engagements


"Call me crazy but I think LinkedIn can POTENTIALLY offer clues about whats happening behind the scenes in psychedelic drug development. Its interesting to observe which companies are growing their teams and which are reducing headcount and also to notice who is engaging with whose posts (especially noticing when leadership at large pharma companies engages with posts) $CMPS $MNMD $CYBN $ATAI $GHRS -Jake"  
[X Link](https://x.com/anyuser/status/1986590145177371103)  2025-11-07T00:22Z [----] followers, [----] engagements


"BREAKING: AbbVies 10-Q discloses a $900M upfront payment related to its acquisition of bretisilocin (GM-2505) from Gilgamesh Pharmaceuticals. Total deal value is up to $1.2B including milestones (as was already disclosed in a PR from AbbVie) Gilgameshs non-GM-2505 programs were spun out into Gilgamesh Pharma Inc. Source: Form 10-Q Filing Date Nov [--] [----] Document Date Sep [--] [----] $CMPS $MNMD $CYBN $ATAI $GHRS"  
[X Link](https://x.com/PsychedVantage/status/1986603667135328695)  2025-11-07T01:16Z [----] followers, [----] engagements


"$ATAI $ARKG Here's every move Cathie Wood and Ark Invest made in the stock market today 11/6 https://t.co/gI4tVrnIhy Here's every move Cathie Wood and Ark Invest made in the stock market today 11/6 https://t.co/gI4tVrnIhy"  
[X Link](https://x.com/PsychedVantage/status/1986617672201900479)  2025-11-07T02:12Z [----] followers, [----] engagements


"Absolutely fascinating data here (yes small sample size). This was looking at IV NN-DMT. I will be super upset and surprised if the CYB004 data isnt stellar. Have been closely following this program for 3-4 years at this point. $CYBN -Jake From: American College of Neuropsychopharmacology Annual Meeting December 8-11 [----] Poster #M59: SPL026 (DMT fumarate) in combination with Selective Serotonin Reuptake Inhibitors (SSRIs) for patients with Major Depressive Disorder (MDD) https://t.co/LYflACTLT9 Absolutely https://t.co/plUPrnf8tC From: American College of Neuropsychopharmacology Annual"  
[X Link](https://x.com/PsychedVantage/status/1986973723233243184)  2025-11-08T01:47Z [----] followers, [----] engagements


"AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003 Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression $ATAI https://ir.ataibeckley.com/news-releases/news-release-details/ataibeckley-announces-positive-topline-data-phase-2b-open-label https://ir.ataibeckley.com/news-releases/news-release-details/ataibeckley-announces-positive-topline-data-phase-2b-open-label"  
[X Link](https://x.com/PsychedVantage/status/1987853518380712278)  2025-11-10T12:03Z [----] followers, [----] engagements


"$ATAI AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003 Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression $ATAI https://t.co/ofdtbKlFAI AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003 Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression $ATAI https://t.co/ofdtbKlFAI"  
[X Link](https://x.com/PsychedVantage/status/1987854263687475406)  2025-11-10T12:06Z [----] followers, [----] engagements


"Were witnessing a fascinating period of innovation in neuropsychiatry. After reading comments from @SriniGRao via @Psyched_Alpha Im encouraged that $ATAI appears to have a clearer understanding of which dose ranges for BPL-003 and VLS-01 may strike the right balance between efficacy and tolerability going forward. I strongly agree with Dr. Raos comment in @Psyched_Alpha: Raos message to the FDA Dont do us any favours. Dont treat these differently. I am a shareholder in $ATAI. This is not medical or financial advice. -Jake"  
[X Link](https://x.com/PsychedVantage/status/1987865662706876578)  2025-11-10T12:51Z [----] followers, [----] engagements


"BPL-003 Phase 2b Open-Label Extension Data $ATAI https://ir.ataibeckley.com/static-files/ddb0a01c-0c09-48aa-9b2c-729b325b0170 https://ir.ataibeckley.com/static-files/ddb0a01c-0c09-48aa-9b2c-729b325b0170"  
[X Link](https://x.com/anyuser/status/1987919021740556542)  2025-11-10T16:23Z [----] followers, [----] engagements


"Im not as optimistic as others about psilocybins potential to treat PTSD/complex PTSD. Im far more optimistic about the benefitrisk profile of MDMA/methylone for PTSD. Genuinely open to being convinced otherwise: what am I missing"  
[X Link](https://x.com/anyuser/status/1988043796773290149)  2025-11-11T00:39Z [----] followers, [----] engagements


"AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London $ATAI https://ir.ataibeckley.com/news-releases/news-release-details/ataibeckley-participate-jefferies-global-healthcare-conference https://ir.ataibeckley.com/news-releases/news-release-details/ataibeckley-participate-jefferies-global-healthcare-conference"  
[X Link](https://x.com/PsychedVantage/status/1988986407172419893)  2025-11-13T15:04Z [----] followers, [----] engagements


"$CMPS $MNMD $CYBN $ATAI $GHRS"  
[X Link](https://x.com/anyuser/status/1989050142360850528)  2025-11-13T19:18Z [----] followers, [----] engagements


"Jefferies Global Healthcare Conference in London $CYBN https://wsw.com/webcast/jeff332/cybn/1843684mobile=True https://wsw.com/webcast/jeff332/cybn/1843684mobile=True"  
[X Link](https://x.com/PsychedVantage/status/1991689265152159807)  2025-11-21T02:04Z [----] followers, [----] engagements


"$CMPS $MNMD $CYBN Cantor's (more comprehensive) 1H26 catalyst watchlist $XBI $BBC https://t.co/PNsLPopjBB Cantor's (more comprehensive) 1H26 catalyst watchlist $XBI $BBC https://t.co/PNsLPopjBB"  
[X Link](https://x.com/PsychedVantage/status/1996077157790183651)  2025-12-03T04:40Z [----] followers, [----] engagements


"Psychedelic Biotech in 2025: What's Next @flobrand and @LarsWilde $ATAI $CMPS $MNMD $CYBN $GHRS https://www.youtube.com/watchv=InxiAa_etho https://www.youtube.com/watchv=InxiAa_etho"  
[X Link](https://x.com/anyuser/status/1998437829311877601)  2025-12-09T17:01Z [----] followers, 10.8K engagements


"@Austinmulder95 I am also in $ATAI $ANRO and $CYBN. I am excited about them as well. Hopefully good Q1 data for all [--] companies on [----] 🤞"  
[X Link](https://x.com/PsychedVantage/status/2000702200121626873)  2025-12-15T22:59Z [----] followers, [---] engagements


"Cybin Initiates At-The-Market Equity Program of up to US$100 Million $CYBN https://ir.cybin.com/investors/news/news-details/2025/Cybin-Initiates-At-The-Market-Equity-Program-of-up-to-US100-Million/default.aspx https://ir.cybin.com/investors/news/news-details/2025/Cybin-Initiates-At-The-Market-Equity-Program-of-up-to-US100-Million/default.aspx"  
[X Link](https://x.com/PsychedVantage/status/2006101854615150719)  2025-12-30T20:35Z [----] followers, [----] engagements


"I really do like $MNMD right now. If I was more comfortable with a long-term bull thesis for them I would buy in a heartbeat. With $ATAI and $CYBN I like them in the short medium and long term. I truly believe $CYBN can eventually become a buyout target and will probably trim shares along the way if those stocks perform the way I think they will. Once you have a drug that may require more than [--] hours in the clinic I do not know if that can scale. $MNMD is now stating that they expect an 8-hour clinic visit on average though. They have an awesome team and plenty of cash and maybe I am missing"  
[X Link](https://x.com/PsychedVantage/status/2008290232094031962)  2026-01-05T21:31Z [----] followers, [---] engagements


"Helus Pharma Corporate Presentation January [----] $HELP https://s28.q4cdn.com/259445127/files/doc_presentations/2026/01/Helus-Corporate-Deck-January-2026.pdf https://s28.q4cdn.com/259445127/files/doc_presentations/2026/01/Helus-Corporate-Deck-January-2026.pdf"  
[X Link](https://x.com/PsychedVantage/status/2008613457911021917)  2026-01-06T18:55Z [----] followers, [---] engagements


"2025 has been quite the year for the psychedelic drug development sector: $CMPS $MNMD $CYBN $ATAI $GHRS We have seen positive mid-late stage data coming from multiple companies across a variety of compounds targeting multiple indications. Nearly $600 million has been raised in follow-on offerings in the past several months and of course big pharma has acquired a compound in the space (and may I add one that doesn't skip the trip) So what do we have to look forward to in [----] This post will focus on clinical trial readouts: $CMPS to disclose 9-week data (Part A) from COMP006 together with"  
[X Link](https://x.com/PsychedVantage/status/1997387574600458677)  2025-12-06T19:28Z [----] followers, [----] engagements


"Big [--] publicly trade companies are $CMPS $MNMD $CYBN $ATAI and $GHRS. You can make an argument that $DRUG is a psychedelic stock with their earlier stage programs. You also have Solvonis Therapeutics Tryptamine Therapeutics (I think they changed their name again to something else) BetterLife Pharma Clearmind Medicine and Enveric Biosciences. Outside of $CMPS $MNMD $CYBN $ATAI $GHRS and $DRUG the rest are nano caps. I am personally most bullish on $ATAI and $CYBN as I hold shares in both. But if you asked me which companies I am most bullish on in short term medium term and longterm I would"  
[X Link](https://x.com/PsychedVantage/status/1997467197376004388)  2025-12-07T00:44Z [----] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing